These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7648311)

  • 1. [Contribution of the experimental model of bacterial endocarditis].
    Carbon C
    Bull Acad Natl Med; 1995 Apr; 179(4):767-74; discussion 775-6. PubMed ID: 7648311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic aspects of therapy of experimental endocarditis.
    Carbon C; Crémieux AC; Fantin B
    Infect Dis Clin North Am; 1993 Mar; 7(1):37-51. PubMed ID: 8463652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental endocarditis: a review of its relevance to human endocarditis.
    Carbon C
    J Antimicrob Chemother; 1993 May; 31 Suppl D():71-85. PubMed ID: 8335526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of endocarditis.
    Carbon C
    Int J Biomed Comput; 1994 Jun; 36(1-2):59-67. PubMed ID: 7927860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis.
    Carbon C
    Scand J Infect Dis Suppl; 1990; 74():163-72. PubMed ID: 2097705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Difficult to treat infections" pharmacokinetic and pharmacodynamic factors--a review.
    Schierholz JM; Beuth J; Pulverer G
    Acta Microbiol Immunol Hung; 2000; 47(1):1-8. PubMed ID: 10735184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of therapy in animal models to bacterial infection in human disease.
    Tunkel AR; Scheld WM
    Infect Dis Clin North Am; 1989 Sep; 3(3):441-59. PubMed ID: 2504810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibiotic therapy of infectious endocarditis (when, with what drug, how long?].
    Schuler G
    Z Kardiol; 1994 Jan; 83(1):2-8. PubMed ID: 8147065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
    Rose WE; Rybak MJ; Kaatz GW
    J Antimicrob Chemother; 2007 Aug; 60(2):334-40. PubMed ID: 17540670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
    Knudsen JD
    Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycoside resistant enterococcal endocarditis.
    Eliopoulos GM
    Infect Dis Clin North Am; 1993 Mar; 7(1):117-33. PubMed ID: 8463648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critique of animal models in antibiotic research.
    Barza M
    Scand J Infect Dis Suppl; 1978; (14):109-17. PubMed ID: 279963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis.
    Rodríguez-Hernández MJ; Jiménez-Mejias ME; Pichardo C; Cuberos L; García-Curiel A; Pachón J
    Clin Microbiol Infect; 2004 Jun; 10(6):581-4. PubMed ID: 15191391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?
    MacGowan A; Rogers C; Bowker K
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S214-20. PubMed ID: 11524721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of infectious endocarditis].
    Blatter M; Frei R; Zimmerli W
    Praxis (Bern 1994); 1994 Nov; 83(47):1324-31. PubMed ID: 7991950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The contribution of experimental models to the physiopathology and treatment of infectious endocarditis].
    Fantin B
    Rev Prat; 1998 Mar; 48(5):492-6. PubMed ID: 9781110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
    Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
    J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.
    Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G
    J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.